Analyst Mike Cikos from Needham maintained a Buy rating on Cellebrite DI (CLBT – Research Report) and keeping the price target at $28.00.
Mike Cikos has given his Buy rating due to a combination of factors, primarily focusing on the anticipated growth in annual recurring revenue (ARR) for Cellebrite DI. The company is expected to see a notable increase in ARR, driven by the upgrade cycle to Inseyets, which has already seen 20% of the installed base migrated by the end of the year. This migration is projected to contribute significantly to ARR growth in the coming years.
Additionally, the company is benefiting from increased attach rates of their unlock solutions, which have risen significantly from the previous year. These factors, combined with the company’s strategic execution towards achieving its CY25 ARR guidance, provide a strong foundation for the Buy rating. The positive trajectory and strategic initiatives suggest a durable growth outlook for Cellebrite DI, justifying the optimistic recommendation by Mike Cikos.